Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both federal and state levels, casting a shadow over ongoing cancer research efforts. Meanwhile, the incidence of cancers—especially gastrointestinal and colorectal cancers among younger populations—is on the rise, heightening the need for new therapeutic approaches. In response, a new generation of biotech companies is stepping forward with promising clinical milestones on the horizon, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Zai Lab Limited (NASDAQ:ZLAB), GeoVax Labs, Inc. (NASDAQ:GOVX), OS Therapies (NYSE-American:OSTX), and SELLAS Life Sciences Group, Inc. (NASDAQ:SLS).